Stocks in Motion: Lexaria Eyes Slice of $90B Weight Loss Market

Shares in innovative drug delivery platform company, Lexaria Bioscience (Nasdaq: LEXX), have been on the rise this week. The company is eyeing a slice of the booming obesity drug market which grew to an astonishing $90 billion in value in 2023, following the success of blockbuster GLP-1 drugs Ozempic® and Wegovy®.

According to Lexaria, an injection-free weight loss solution that doesn’t cause stomach upsets could be closer than we think. The company’s DehydraTECH drug delivery technology enables improved and more rapid absorption of drugs into the bloodstream and brain tissues. Lexaria has demonstrated in a number of studies that its DehydraTECH formulations begin to take effect in as little as 1.5 minutes after dosing, and that intestinal bioabsorption of bioactive compounds is increased by as much as 17x. The result is greater bioavailability of therapeutics at reduced doses.

Lexaria announced on Friday that it has engaged a contract research organization (CRO) to perform the company’s second DehydraTECH-powered GLP-1 human pilot study which will compare three dose formulations: DehydraTECH-semaglutide swallowed capsules, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet, and a positive control Rybelsus® swallowed tablet.

“DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the buccal/sublingual tissues of the mouth and throat,” said Chris Bunka, Lexaria’s CEO. “If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets, could be within reach.”

This week, Lexaria also announced that it will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination in a 12-week animal study. The company previously demonstrated weight loss of 7% and a statistically significant reduction of 19.9% in blood glucosein an eight week animal study.

Lexaria will also evaluate its DehydraTECH technology in the treatment of hypertension after it received FDA clearance of an investigational new drug (IND) application for a Phase 1b hypertension clinical trial. Lexaria has demonstrated significant reductions in resting blood pressure in five human clinical studies of DehydraTECH-CBD in healthy normal and hypertensive volunteers, suggesting that DehydraTECH-CBD has the potential to deliver pronounced clinical benefits relative to available anti-hypertensive therapeutics.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

About the Author:

Applied Therapeutics Charts Path Forward After FDA Setback, Eyes European Approval and Pipeline Expansion

Editor Prism MarketView

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida.